ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary Endpoint

ZeJing Pharma announced on May 7 that its independently developed injectable human thyrotropin beta has achieved the primary endpoint in its Phase III clinical trial. According to Jin10, the study, titled 'Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Study on the Efficacy and Safety of Recombinant Human Thyrotropin in Postoperative Radioiodine Therapy for Differentiated Thyroid Cancer Patients,' demonstrated expected efficacy and safety results. The trial met the pre-set primary endpoint. The company plans to submit a Pre-BLA communication application to the CDE to actively advance the market approval process for this indication. Detailed data from the study will be presented at future international or domestic clinical academic conferences.